Is IOL Chemicals And Pharmaceuticals a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that IOL Chemicals And Pharmaceuticals Ltd is a below average quality company .

Is IOL Chemicals And Pharmaceuticals undervalued or overvalued?

The key valuation ratios of IOL Chemicals And Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is IOL Chemicals And Pharmaceuticals share price return in the past 10 years?

IOL Chemicals And Pharmaceuticals Ltd share price has appreciated 26% annually (CAGR) over the past ten years.

Is IOL Chemicals And Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of IOL Chemicals And Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the P/E ratio of IOL Chemicals And Pharmaceuticals?

The latest standalone P/E ratio of IOL Chemicals And Pharmaceuticals as of 20-Dec-2024 is 24.61.

What is the P/B ratio of IOL Chemicals And Pharmaceuticals?

The latest standalone P/B ratio of IOL Chemicals And Pharmaceuticals as of 20-Dec-2024 is 1.49.

What is the 52-week high and low of IOL Chemicals And Pharmaceuticals?

The 52-week high of IOL Chemicals And Pharmaceuticals is Rs. 537.05 and the 52-week low is Rs. 333.00.

What is the TTM revenue of IOL Chemicals And Pharmaceuticals?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of IOL Chemicals And Pharmaceuticals is Rs. 2052.44 (Cr.).

IOL Chemicals And Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: IOL Chemicals And Pharmaceuticals
Brand: IOL Chemicals And Pharmaceuticals

BSE: 524164 | NSE: IOLCP | Pharmaceuticals & Drugs | Small Cap

Place order

IOL Chem & Pharma Share Price

₹420.30 -21.40 -4.84%
as on 20-Dec'24 16:59

10 Year X-Ray of IOL Chem & Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	0%	0%	0%	0%	0%	0%	0%	16.3%	13.6%	12.2%	-
Value Creation Index ⓘ	NA	NA	NA	NA	NA	NA	NA	0.2	0.0	-0.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	0	0	0	0	2,184	2,217	2,133	2,052
Sales YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	1.5%	-3.8%	-
Adj EPS ⓘ	0	0	0	0	0	0	0	27.5	22.9	21.3	17
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	-16.5%	-7%	-
BVPS (₹) ⓘ	0	0	0	0	0	0	0	237.2	256.8	274.5	282.6
Adj Net Profit ⓘ	0	0	0	0	0	0	0	161	135	125	100
Cash Flow from Ops. ⓘ	0	0	0	0	0	0	0	93.1	122	290	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0.5	0.7	0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	NA	NA	-3.8%
Adj EPS ⓘ	NA	NA	NA	-7%
BVPSⓘ	NA	NA	NA	6.9%
Share Price	26%	20.1%	-1.4%	-8.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	11.6	9.3	8	6.1
Op. Profit Mgn % ⓘ	11.9	10.2	10.8	9.1
Net Profit Mgn % ⓘ	7.4	6.1	5.9	4.9
Debt to Equity ⓘ	0	0.1	0	0
Working Cap Days ⓘ	0	198	194	96
Cash Conv. Cycle ⓘ	0	75	75	49

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 6.10%

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at -7.29%

Latest Financials - IOL Chemicals And Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	17.1	17
TTM Sales (₹ Cr.)	2,052	2,052
BVPS (₹.) ⓘ	282.6	282.6
Reserves (₹ Cr.) ⓘ	1,601	1,601
P/BV ⓘ	1.49	1.49
PE ⓘ	24.61	24.72

From the Market
52 Week Low / High (₹)	333.00 / 537.05
All Time Low / High (₹)	0.33 / 898.40
Market Cap (₹ Cr.)	2,467
Equity (₹ Cr.)	58.7
Face Value (₹)	10
Industry PE ⓘ	44.3

Management X-Ray of IOL Chem & Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of IOL Chem & Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of IOL Chem & Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'22	Mar'23	Mar'24
Sales	2,184	2,217	2,133
Operating Expenses ⓘ	1,926	1,991	1,902
Manufacturing Costs	115	175	197
Material Costs	1,571	1,547	1,397
Employee Cost	141	168	201
Other Costs ⓘ	99	101	108
Operating Profit ⓘ	258	226	231
Operating Profit Margin (%)	11.8%	10.2%	10.8%
Other Income ⓘ	32	26	30
Interest ⓘ	8	16	16
Depreciation ⓘ	43	46	63
Exceptional Items ⓘ	-14	0	0
Profit Before Tax ⓘ	225	189	182
Tax ⓘ	57	50	47
Profit After Tax	168	139	134
PAT Margin (%)	7.7%	6.3%	6.3%
Adjusted EPS (₹)	28.6	23.7	22.9
Dividend Payout Ratio (%)	14%	17%	22%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	1,392	1,508	1,612
Share Capital ⓘ	59	59	59
Reserves ⓘ	1,334	1,449	1,553
Minority Interest	0	0	0
Debt	43	80	33
Long Term Debt	0	0	0
Short Term Debt	43	80	33
Trade Payables	409	314	469
Others Liabilities ⓘ	180	167	168
Total Liabilities ⓘ	2,024	2,068	2,282
Fixed Assets
Gross Block	762	995	1,237
Accumulated Depreciation	201	243	304
Net Fixed Assetsⓘ	561	752	933
CWIP ⓘ	105	90	101
Investmentsⓘ	2	20	20
Inventories	410	326	425
Trade Receivables	470	505	471
Cash Equivalents	140	22	143
Others Assetsⓘ	336	354	188
Total Assets ⓘ	2,024	2,068	2,282

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	93	122	290
PBT ⓘ	225	189	182
Adjustment ⓘ	33	44	60
Changes in Working Capital ⓘ	-102	-64	90
Tax Paid ⓘ	-63	-47	-42
Cash Flow From Investing Activity ⓘ	-121	-120	-191
Capex	-151	-210	-272
Net Investments	22	80	67
Others ⓘ	8	9	14
Cash Flow From Financing Activityⓘ	-2	-4	-93
Net Proceeds from Shares ⓘ	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0
Interest Paid ⓘ	-8	-16	-16
Dividend Paid ⓘ	-35	-24	-29
Others ⓘ	42	36	-47
Net Cash Flow ⓘ	-29	-2	6

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	12.04	9.6	8.62
ROCE (%)	16.25	13.57	12.24
Asset Turnover Ratio	1.08	1.08	0.98
PAT to CFO Conversion(x)	0.55	0.88	2.16
Working Capital Days
Receivable Days	79	80	84
Inventory Days	69	61	64
Payable Days	95	85	102

IOL Chemicals And Pharmaceuticals Ltd Stock News

IOL Chemicals And Pharmaceuticals Ltd FAQs

What is the share price of IOL Chem & Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of IOL Chem & Pharma on 20-Dec-2024 16:59 is ₹420.3.

What is the market cap of IOL Chem & Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of IOL Chem & Pharma stood at ₹2,467.4.

What is the P/E ratio of IOL Chem & Pharma?

The latest P/E ratio of IOL Chem & Pharma as of 20-Dec-2024 16:59 is 24.61.

What is the P/B ratio of IOL Chem & Pharma?

The latest P/B ratio of IOL Chem & Pharma as of 20-Dec-2024 16:59 is 1.49.

What is the 52-week high and low of IOL Chem & Pharma?

The 52-week high of IOL Chem & Pharma is ₹537.0 and the 52-week low is ₹333.0.

What is the TTM revenue of IOL Chem & Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of IOL Chem & Pharma is ₹2,052 ( Cr.) .

About IOL Chemicals And Pharmaceuticals Ltd

IOL Chemicals and Pharmaceuticals (IOLCP) is a leading organic chemicals manufacturers and suppliers. They are Indian manufacturer of industrial chemicals & bulk drugs for over two decades, by pursuing & implementing the highest standards of excellence in their operations, they have nurtured their capabilities by delivering consistent results and have earned the admiration of customers and stakeholders alike.

IOLCP has attained a front line position in the domestic segment and is thus contemplating to widen its horizon through global penetration. It has overseas customers from various countries like Bangladesh, Thailand, UAE, Syria, Singapore, Hong Kong, Pakistan, Egypt and many others.

IOLCP is therefore moving ahead with its vision to develop global strategic alliances with quality leaders and expand into new markets.

Product range of the company includes:

Acetic AcidWith a production capacity of 6.5 million metric tonnes, Acetic Acid is a significant chemical reagent & industrial chemical with a wide spectrum of applications.
Ethyl Acetate Ethyl Acetate is a significant industrial solvent with diverse industrial applications.
Acetic AnhydrideAcetic Anhydride is a well-known acid anhydride that is widely used in pharmaceutical & agrochemical industries.
Isobutyl BenzeneThis specialty chemical is used as an intermediate in Ibuprofen and other anti-inflammatory analgesic bulk drug
Mono Chloro Acetic AcidAlso know as Chloro Acetic Acid it is used in agrochemicals, pesticides, insecticides, organic chemicals etc.
Acetyl ChlorideAcetyl Chlorideis is colourless, near to pale yellow liquid that is used in perfume, dye, chemical, pharmaceutical bulk drugs and intermediates.
Ibuprofen A non-steroidal anti-inflammatory drug, Ibuprofen is used in the treatment of a variety of ailments such as arthritis, dysmenorrhoea, and is also used an analgesic.

Clientele:

They have strong business relationships with a number of prestigious clients such as Ranbaxy Labs, CIPLA, Flex Industries, ICI Paints, Asian Paints, Pidilite, Rallis India, Hindustan Polymide, Gujarat Super Phosphate, & Avon Organics etc.

Awards & Achievements:

IOL Chemicals & Pharmaceuticals has consecutively been bestowed with the 2nd Prize in Chemical Sector-National Energy Conservation Award 2007, by the Ministry of Power, Government of India for the third time in a row for its efforts made towards new technology implementation to conserve the energy resources of the company.
IOLCP has also won Kamla Dial Gold Standard for North-West Qual Tech Standards-2006 conducted by Qimpro College Mumbai.
One star Export House Status Award.
National Energy Conservation Award 2007.
National Energy Conservation Award 2006.
National Energy Conservation Award 2005.
One star export House Status Award.
Halal Certification.
Kosher Certification.
USFDA Certification.
EDQM Certification.

Future Plans:

Chemicals Expansion - The company has planned for increasing the capacity of Acetic Acid from 50000 TPA to 66000 TPA, Ethyl Acetate from 33000 TPA to 36000 TPA & Capacity of Acetic Anhydride from 12000 TPA to 18000 TPA.
Pharma Expansion - IOLCP recently boosted its Ibuprofen plant capacity to 3600 TPA from 1800 TPA and to further expand the capacity to 6000 TPA.
PPI's - The company has planned for installation of new manufacturing facilities of following PPIs:-Rabeprazole -Lansoprazole -Omeprazole -Pantoprazole -Esomeprazole. With annual installed capacity of 360 MT, the commercial production will start by the end of 2008.
Co-generation Power Plant - To meet out its enhanced energy requirement and to become self reliance the company has also proposed for another captive co-generation plant with additional capacity of 13 MW in addition to the existing cogeneration plant of 4 MW capacity.
Forward Integration - The company has planned for adding two more products i.e. Mono Chloro Acetic Acid(MCA) with a capacity of 6600 TPA & Acetyl Chloride with a capacity of 4800 TPA , using Acetic Anhydride & Acetic Acid as a raw material.
Backward Integration - The company has planned for setting up plant for Iso-butyl Benzene(IBB) with a capacity of 6000 TPA which will be the raw material for the manufacturing of Ibuprofen.
Research & Development - To develop new Molecules and process development